Diagnosis and treatment of systemic mastocytosis: state of the art. - Wikidata - awgldk - TriplyDB

Diagnosis and treatment of systemic mastocytosis: state of the art.

Diagnosis and treatment of systemic mastocytosis: state of the art.

http://www.wikidata.org/entity/Q35203889

about

Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology Mast Cell Clonal Disorders: Classification, Diagnosis and Management Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth High prevalence of anaphylaxis in patients with systemic mastocytosis - a single-centre experience.Phenotypic and genotypic characteristics of mastocytosis according to the age of onset.Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens.Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future.Mastocytosis: state of the art.Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.Long-lasting complete response to imatinib in a patient with systemic mastocytosis exhibiting wild type KIT.Interleukin-9 (IL-9) and NPM-ALK each generate mast cell hyperplasia as single 'hit' and cooperate in producing a mastocytosis-like disease in mice.Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Childhood mastocytosis: results of a single center.Systemic mastocytosis presenting with gastrointestinal, bone and skin involvement Mastocytosis: pathology, genetics, and current options for therapy.Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.Systemic mastocytosis: bone marrow pathology, classification, and current therapies.Systemic mastocytosis associated with chronic idiopathic myelofibrosis: a distinct subtype of systemic mastocytosis associated with a [corrected] clonal hematological non-mast [corrected] cell lineage disorder carrying the activating point mutations Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Chronic mast cell leukemia (MCL) with KIT S476I: a rare entity defined by leukemic expansion of mature mast cells and absence of organ damage.Clinical immunology review series: an approach to the patient with anaphylaxis.Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.Preclinical and clinical experience with dasatinib in Philadelphia chromosome-negative leukemias and myeloid disorders.Update on genetic and molecular markers associated with myelodysplastic syndromes.FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H Allergic mastocytic gastroenteritis and colitis: an unexplained etiology in chronic abdominal pain and gastrointestinal dysmotility.Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders Severe chronic diarrhea and maculopapular rash: a case report Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts.Current concepts on diagnosis and treatment of mastocytosis.Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis.H1-receptor antagonists terfenadine and loratadine inhibit spontaneous growth of neoplastic mast cells.AR-42, a novel HDAC inhibitor, exhibits biologic activity against malignant mast cell lines via down-regulation of constitutively activated Kit.Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology.

P2860

Q24685914-3704C38C-C4F3-4D78-96F4-0ECF93C2F537 Q28070386-1DFF4E59-05D6-4246-A1F8-77BFB5CE8BFA Q28828739-3EE536F2-B515-431E-BF7A-13697BA6F4F8 Q33163450-D6FE6B7F-0410-4C14-9B08-D834A4625105 Q33327689-9EC5EF3F-8B09-4D3B-8655-A130F40271C7 Q33423072-98F2CB2F-9294-407D-B10D-D12AFAA60D5A Q34293285-95EBB1E1-495F-4908-8A9F-EA7477959BEF Q34300709-CE74FE6A-AB03-41BD-93AD-8EAED1853E3C Q34552564-4351E566-0C74-4245-BB4E-816A19D19774 Q34641105-C7ED5447-A320-4106-95BC-011DE376BC02 Q34663691-3FC6BB64-3EBE-4DDF-8A71-BF078EE5600A Q35153623-76B86922-4535-476A-B848-073C7533C2F2 Q35169575-83EFD039-C510-4E99-BD82-A9F62EFA5D1F Q35587647-31B482B5-534F-45A4-A055-961D31871C43 Q35848377-607B28D5-8D17-47D1-B0FD-8B88BA64AB19 Q35854970-13943E36-6FDC-41F1-8B60-51B525074A6A Q35913666-2524057C-268A-4BDB-AA73-7045FF2AEC8C Q35929253-3CC4EC99-CEEC-4822-B77D-9AA3B6E1202F Q35994902-0D795C83-C505-4DA8-BAEE-F15478FED703 Q36182744-82DE38B0-5E22-49A4-94B3-818A23148976 Q36182749-23D0E94D-B761-4081-AF13-14B2C6E1252C Q36329321-7FDB8C96-4595-4BAA-A23F-EC52AEF139DA Q36406996-74183B44-50BA-44B2-95D5-70A2B58198AE Q36842503-03E48C6F-D319-4BF6-945C-9CF129A4815A Q36977300-10EF9B9D-C8D7-43D1-8149-B3388D33A4CE Q37199236-F1563CE6-53C3-41DD-AE04-821B2ACFD7D8 Q37247964-9D55A6EF-38F0-4C5B-BB66-0A8E804EF2EC Q37327244-6788ED8B-1407-432D-A14D-921DDA9DB7BE Q37407161-7B30E778-BF1B-4D66-9DCD-BBE297A31B3F Q37611613-089C85A5-44CA-45D0-8C14-9E6BEF8BD87C Q38009308-4B3507E2-63BB-49A5-9FD1-C54BEB510C14 Q38202204-087BFD33-E9BC-4073-A13E-269708547588 Q38773595-5AB59257-D447-4BA6-A74D-7A20E82DAC6B Q38777126-E5A276A7-76C7-48BA-A20A-920978C4A3CC Q38978981-49FB6CE1-F214-4CDA-826F-A57BFB40B008 Q39606792-39F44051-6935-407E-A536-2A9D613C39FB Q39615506-AE184D4F-43B1-4A49-A5F2-D93D5220CA16 Q39689493-430BCA1B-97C8-4EFC-8C81-F40E3699D147 Q39726849-516A8198-967C-4478-A918-E88E6D3826ED Q39779573-B046EF7A-2BDE-4954-8535-E13A41FD3596

P2860

Diagnosis and treatment of systemic mastocytosis: state of the art.

http://www.wikidata.org/entity/Q35203889

description

2003 nî lūn-bûn

@nan

2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Diagnosis and treatment of systemic mastocytosis: state of the art.

@ast

Diagnosis and treatment of systemic mastocytosis: state of the art.

@en

type

label

Diagnosis and treatment of systemic mastocytosis: state of the art.

@ast

Diagnosis and treatment of systemic mastocytosis: state of the art.

@en

prefLabel

Diagnosis and treatment of systemic mastocytosis: state of the art.

@ast

Diagnosis and treatment of systemic mastocytosis: state of the art.

@en

P1433

Q35203889-C429E721-CDB4-4F79-9457-D443E815BC10

P1476

Q35203889-7D368A10-D3DC-4CBD-976D-A0C26EBD576E

P2093

Q35203889-06486CE6-2CEA-43FF-B3F1-2A957F535635

Q35203889-09ECCB0E-1F86-4DA9-A345-AD7DABF3B1BE

Q35203889-0B41D061-9362-40E8-B29A-45C15396F54C

Q35203889-211B3B8A-365D-4FA8-9CA7-9FC70D0C995F

Q35203889-998DF1CA-A662-4E4C-B3CD-D6E0B83DECB7

Q35203889-ACBF1384-4B72-4164-8379-929057EA5CA5

Q35203889-BD88E505-0E38-41AA-A056-342DC7DA9A32

Q35203889-C53FF5EA-91B8-44B7-A7AC-5A859FF12C2F

P2860

Q35203889-07B88A97-E24C-4D43-8341-EC31E0173A3F

Q35203889-0873CE9E-462E-46D5-A05F-B788FAB6ADCA

Q35203889-0DE1D625-ED3E-4558-8796-2A5045CDAB90

Q35203889-0EBFEDED-61AD-4931-94D8-3D58B924973B

Q35203889-0FFDF49E-A55C-4562-9AD9-9F13F2F1E7F3

Q35203889-1458E8EB-BD59-490F-8747-C4E35B04343F

Q35203889-16EFB508-FAF4-4684-A716-374B8A833F26

Q35203889-19072D43-E18D-4945-8580-D6D779CCB5DA

Q35203889-1B059116-AE04-41B0-BA56-5B808AB50107

Q35203889-21BB5C63-AF73-4849-A1EF-4C1A36D9B986

P304

Q35203889-BFAB776A-D536-4EEE-85B8-291992B45BD8

P31

Q35203889-5E4F3555-376F-422B-B9A8-E9CBCDE31B5A

P356

Q35203889-BD4D30F5-F093-4EBD-845D-651672811D2D

P407

Q35203889-BB073410-6424-4081-9930-23A342FCD513

P433

Q35203889-FA9C0C43-5B95-4529-A8ED-6F184FA05198

P478

Q35203889-D288BE13-CAD3-4650-9928-A8F2C4511713

P577

Q35203889-F9DBF9FA-A090-4F90-B361-136F84FEA3D1

P5875

Q35203889-33C8DFEC-CFFA-49B9-9065-984E53E83E40

P698

Q35203889-FC82F325-21D0-48C7-9332-AA8F8683CB21

P356

J.1365-2141.2003.04575.X

P1433

British Journal of Haematology

P1476

Diagnosis and treatment of systemic mastocytosis: state of the art.

@en

P2093

Cem Akin

http://www.w3.org/2001/XMLSchema#string

Dean D Metcalfe

http://www.w3.org/2001/XMLSchema#string

Hans-P Horny

http://www.w3.org/2001/XMLSchema#string

John M Bennett

http://www.w3.org/2001/XMLSchema#string

Klaus Lechner

http://www.w3.org/2001/XMLSchema#string

Michel Arock

http://www.w3.org/2001/XMLSchema#string

Peter Valent

http://www.w3.org/2001/XMLSchema#string

Wolfgang R Sperr

http://www.w3.org/2001/XMLSchema#string

P2860

Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis

Treatment of cutaneous mastocytosis

Temporary response of localized intracranial mast cell sarcoma to combination chemotherapy.

A case of 'smouldering' mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val.

Mastocytosis: mediator-related signs and symptoms.

Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis.

Increased bone marrow mast cells in preleukemic syndromes, acute leukemia, and lymphoproliferative disorders.

Response of severe systemic mastocytosis to interferon alpha.

Recent advances in mastocytosis research. Summary of the Vienna Mastocytosis Meeting 1998.

Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis.

P304

695-717

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1365-2141.2003.04575.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

122

http://www.w3.org/2001/XMLSchema#string

P577

2003-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10604828

http://www.w3.org/2001/XMLSchema#string

P698

12930381

http://www.w3.org/2001/XMLSchema#string